Objective End‐stage renal disease (ESRD) is a major consequence of lupus nephritis, but
how this risk has changed over time is unknown. We conducted this systematic review to …

The introduction of biologic DMARDs into rheumatology has resulted in a substantial
reduction of the burden of many rheumatic diseases. In the slipstream of the success …

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to
provide guidance on the management of immune-related adverse events resulting from …

The principle of treating-to-target has been successfully applied to many diseases outside
rheumatology and more recently to rheumatoid arthritis. Identifying appropriate therapeutic …

Background Systemic lupus erythematosus (SLE) is an autoimmune disease with a
prevalence of 36.7/100 000 in Germany and a female/male ratio of 4: 1. The clinical course …

Systemic lupus erythematosus (SLE) is a chronic, multiorgan, systemic autoimmune disease
that is more common in women than men and is typically diagnosed during reproductive …

Objectives To evaluate changes in demographic, clinical and histological presentation, and
prognosis of lupus nephritis (LN) over time. Patients and methods We studied a multicentre …

Objective Management of systemic lupus erythematosus (SLE) is complex and variability in
practices exists. Guidelines have been developed to help improve the management of SLE …

Background To perform a systematic review and network meta-analysis (NMA) to compare
the risk of serious infections with immunosuppressive medications and glucocorticoids in …

Background Cyclophosphamide, in combination with corticosteroids, has been first‐line
treatment for inducing disease remission for proliferative lupus nephritis, reducing death at …